abstract Current therapies for immune-mediated inflammatory disorders in peripheral nerves are non-specific, and partly efficacious. Peripheral nerve regeneration following axonal degeneration or injury is suboptimal, with current therapies focused on modulating the underlying etiology and treating the consequences, such as neuropathic pain and weakness. Despite significant advances in understanding mechanisms of peripheral nerve inflammation, as well as axonal degeneration and regeneration, there has been limited translation into effective new drugs for these disorders. A major limitation in the field has been the unavailability of reliable disease models or research tools that mimic some key essential features of these human conditions. A relatively overlooked aspect of peripheral nerve regeneration has been neurovascular repair required to restore the homeostatic microenvironment necessary for normal function. Using Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as examples of human acute and chronic immune-mediated peripheral neuroinflammatory disorders respectively, we have performed detailed studies in representative mouse models to demonstrate essential features of the human disorders. These models are important tools to develop and test treatment strategies using realistic outcomes measures applicable to affected patients. In vitro models of the human blood-nerve barrier using endothelial cells derived by endoneurial microvessels provide insights into pro-inflammatory leukocyte-endothelial cell interactions relevant to peripheral neuroinflammation, as well as potential mediators and signaling pathways required for vascular proliferation, angiogenesis, remodeling and tight junction specialization necessary to restore peripheral nerve function following injury. This review discusses some of the progress being made in translational peripheral neurobiology and some future directions.
. Neuropathic pain is potentially disabling and may affect over 1% of the United States population [1, 4] . Current treatments for peripheral neuropathies and neuropathic pain are non-specific and in many cases, partly effective at best and associated with considerable side effects [1, 5, 6] . The direct health care cost runs into several billion U.S. dollars per annum, excluding losses from reduced productivity [7] . Of particular interest to our research laboratory are the primary acute and chronic autoimmune inflammatory peripheral nerve disorders.
Guillain-Barré syndrome (GBS) is the most common cause of rapidly progressive, potentially life-threatening weakness in industrialized nations. GBS is a disorder that commonly develops days to weeks after certain bacterial or viral infections or minor trauma. This observation suggests an autoimmune response related to molecular mimicry of peripheral nerve antigens, including gangliosides [8] [9] [10] . GBS is characterized by demyelination, axonal degeneration or both that is restricted to nerve roots and peripheral nerves. This causes weakness, loss of sensation and cardiovascular instability that may progress to respiratory failure and death [11, 12] . The likelihood of permanent disability or death is related to the severity of weakness [8] [9] [10] .
Based on 2004 estimates, the total average annual cost of GBS to the United States was ~$1.7 billion [13] . The most common variant of GBS, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), is associated with nerve root and peripheral nerve infiltration by hematogenous monocytes/ macrophages, T-cells and B-cells/plasma cells.
There is pathological evidence of cell and humoral-mediated demyelination and axonal injury [8] [9] [10] . Although the precise trigger for autoimmune attack is unknown, inhibition of leukocyte infiltration at the early stages could reduce the extent of demyelination and axonal injury, improving patient outcomes in GBS. Despite advances in molecular biology and genetics, there have been no new GBS treatments or significant improvements in patient outcomes over the last 20 years [10, 14] . [17, 18] . Although the precise trigger for the autoimmune attack is also unknown, preventing early leukocyte infiltration could reduce the extent of demyelination and axonal injury, improving patient outcomes in CIDP [6] . and axonal loss (reduced distal compound motor action potential amplitudes) in the dorsal caudal tail and sciatic nerves [37] .
Increased expression of pro-inflammatory chemokines has been described in the peripheral nerves and cerebrospinal fluid of patients with GBS compared to controls [40] [41] [42] [43] . We have demonstrated up-regulation in specific pro-inflammatory chemokine ligand-receptor pairs (CCL2-CCR2, CCL5-CCR1/ CCR5 and CXCL10-CXCR3) in the sciatic nerves of affected mice at peak severity relative to unaffected controls [44] . We demonstrated CCL2 expression by Schwann cells and CCR2 on endoneurial macrophages implying a role for CCL2-CCR2 in macrophage-induced demyelination in sm-EAN [44] as suggested by observational studies in human nerve biopsies [42] . Macrophage-induced demyelination is a characteristic hallmark of AIDP.
CCL5 was expressed by axons, with CCR1 and CCR5 predominantly expressed on endoneurial Figure 1 . Histopathological features of sm-EAN. Representative toluidine-blue stained, basic fuchsin counterstained photomicrographs of 1 µm glutaraldehyde fixed, osmium tetroxide post-fixed plasticembedded mouse sciatic nerve axial sections show the normal distribution of myelinated axons in control female SJL/J mice (A) in contrast to the severe demyelination and reduction in axonal density coupled with mononuclear cell infiltration in sm-EAN at peak severity (B). The extent of intense mononuclear cell infiltration in sm-EAN is depicted by the 4' ,6-diamidino-2-phenylindole (DAPI)-stained photomicrographs of 10 µm frozen sciatic nerve axial sections (D) compared to unaffected controls (C). Sm-EAN is associated with demyelination, as demonstrated by fragmentation of Schwann cell S100β (green) immunoreactivity (E), and axonal loss depicted by reduced neurofilament-H (red) immunoreactivity (F) as described in nerve biopsies of human AIDP. Mononuclear leukocyte infiltration consists predominantly of F4/80+ macrophages (red immunoreactivity, G), followed by T-cells (H) and B-cells (I), depicted by green immunoreactivity. Blue depicts nuclei (DAPI stain). Kindly refer to [37] CXCL10 had been implicated in GBS pathogenesis based on sural nerve biopsy data from affected patients [40] .
Chemokine receptors are G-protein coupled receptors, a family of receptors to which over 50% of known drugs directly target [45, 46] . In vitro models of the human blood-nerve barrier: peripheral neuroinflammation [66] [67] [68] [69] [70] [71] [72] [73] [74] .
We infer from our study that Schwann cells may be responsible to some extent in human bloodnerve barrier recovery following peripheral nerve injury via paracrine secretion that directly acts on GFRα1-expressing endoneurial endothelial cells [64] . Using continuous . GDNF and its signaling pathways in the recovery of human blood-nerve barrier resistance in vitro following serum withdrawal. Using continuous electrical cell impedance sensing, primary human endoneurial endothelial cells cultured on glutaraldehyde-crosslinked rat tail collagen-coated wells achieve steady transendothelial electrical resistance 5 days after plating (A). Following serum withdrawal from confluent cultures (B) with concomitant inclusion of 1 ng/mL GDNF (black arrow), there is a rapid drop in resistance for about 18 hours followed by a gradual improvement in resistance over the next 30 hours. This response with the in vitro blood-nerve barrier (IVBNB) is dose-dependent (C), and maximal with 1 ng/mL GDNF, as observed in our published study using transwell inserts. GDNF-mediated recovery in IVBNB resistance is dependent on RET-tyrosine kinase (RET-TK) signaling with evidence supporting downstream involvement of the mitogen activated protein kinase pathway, demonstrated by inhibition with specific cell-permeable inhibitors against RET-TK and ERK1/2 (D), respectively. * indicates p<0.05 for these preliminary experiments.
peripheral nerve regeneration following injury in rodent models [59, 60, 62, 63] primary endoneurial endothelial cell proliferation relative to basal proliferation without added mitogens using the non-radioactive WST-1 assay is shown, with maximal proliferation observed with 10 and 50 ng/mL (A). Using a 4hr Matrigel ® angiogenesis assay, 0.1 ng/mL VEGF 165 maximally increased the mean number of microvessels (B) and their mean total length (C) per field (1700 µm X 1270 µm) in a dose-dependent manner relative to basal medium without added mitogens. A sterile micropipette wound healing assay performed on confluent primary endoneurial endothelial cell cultures demonstrates a dose-dependent rate of recovery (based on endothelial cell migration across the deficits between 4-18 hours after the injury), maximal with 10 ng/mL VEGF (D). Interestingly, 10 ng/mL VEGF 165 induced complete wound healing between 18-30 hours after injury by endothelial cell proliferation. The VEGF-mediated effects on proliferation, angiogenesis and wound healing are significantly enhanced by heparin (data not shown). * indicates p<0.05 for these preliminary experiments. 
